Versant Capital Management Inc Invests $54,000 in Sanofi (NASDAQ:SNY)

Versant Capital Management Inc acquired a new stake in shares of Sanofi (NASDAQ:SNY) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund acquired 1,116 shares of the company’s stock, valued at approximately $54,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Northwest Investment Counselors LLC purchased a new position in shares of Sanofi during the 3rd quarter valued at $29,000. Concord Wealth Partners boosted its position in Sanofi by 157.8% during the third quarter. Concord Wealth Partners now owns 593 shares of the company’s stock valued at $34,000 after purchasing an additional 363 shares during the last quarter. Sunbelt Securities Inc. increased its position in Sanofi by 72.1% in the 3rd quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after purchasing an additional 313 shares during the last quarter. Fortitude Family Office LLC raised its stake in shares of Sanofi by 708.6% during the 3rd quarter. Fortitude Family Office LLC now owns 752 shares of the company’s stock worth $43,000 after purchasing an additional 659 shares in the last quarter. Finally, Ashton Thomas Private Wealth LLC acquired a new stake in shares of Sanofi during the 2nd quarter valued at about $51,000. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $48.15 on Monday. The business’s 50-day simple moving average is $49.13 and its 200-day simple moving average is $52.07. Sanofi has a 52 week low of $45.22 and a 52 week high of $58.97. The company has a debt-to-equity ratio of 0.17, a quick ratio of 0.65 and a current ratio of 1.00. The firm has a market cap of $122.20 billion, a price-to-earnings ratio of 24.57, a P/E/G ratio of 1.23 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Friday, October 25th. The company reported $1.57 earnings per share for the quarter, topping analysts’ consensus estimates of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The business had revenue of $13.44 billion during the quarter, compared to analysts’ expectations of $16.59 billion. During the same period in the previous year, the company earned $2.55 earnings per share. Sanofi’s revenue for the quarter was up 12.3% on a year-over-year basis. As a group, equities research analysts expect that Sanofi will post 4.06 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on SNY shares. StockNews.com downgraded Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a research note on Tuesday, September 17th. Two analysts have rated the stock with a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.